Safety of bevacizumab (BV) plus docetaxel (D) in patients (pts) with locally recurrent (LR) or metastatic breast cancer (mBC) who developed brain metastases during the AVADO phase III study

被引：0
|
作者：
Dirix, L. Y.
Romieu, G.
Provencher, L.
Grimes, D.
de Souzo, Viana L.
Paterson, A.
Mauriac, L.
Kirsch, A.
Pernas, S.
Miles, D. W.
机构：
[1] Oncol Ctr AZ St Augustinus Oncol, Antwerp, Belgium
[2] CRLCC Val Aurelle, Montpellier, France
[3] Hop St Sacrement, Quebec City, PQ, Canada
[4] Brisbane Haematol Oncol Clin, Auchenflower, Australia
[5] Hosp Canc Barretos, Barretos, Brazil
[6] Tom Baker Canc Clin, Calgary, AB, Canada
[7] Inst Bergonie, Bordeaux, France
[8] Onkol Schwerpunki Oskar Helene Heim, Berlin, Germany
[9] Inst Catala Oncol, Barcelona, Spain
来源：
CANCER RESEARCH | 2009年 / 69卷 / 02期
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
引用
收藏
页码：285S / 285S
页数：1
相关论文
共 50 条
  • [21] Polymorphism Analysis in the AVADO Randomised Phase III Trial of First-line Bevacizumab (BEV) Combined With Docetaxel in HER2-negative Metastatic Breast Cancer (mBC)
    Miles, D. W.
    De Haas, S. L.
    Romieu, G.
    Chan, A.
    Dirix, L.
    Cortess, J.
    Delmar, P. R.
    Scherer, S. J.
    EUROPEAN JOURNAL OF CANCER, 2011, 47 : S176 - S176
  • [22] Phase II study of bavituximab plus docetaxel in patients with locally advanced or metastatic breast cancer
    Tabagari, D.
    Nemsadze, G.
    Jincharadze, M.
    Janjalia, M.
    Shan, J. S.
    JOURNAL OF CLINICAL ONCOLOGY, 2009, 27 (15)
  • [23] Safety and efficacy of first-line bevacizumab (B) plus chemotherapy (CT) for locally recurrent or metastatic breast cancer (LR/mBC): Analysis of MO19391 according to CT
    Pierga, J.
    Pritchard, K. I.
    Thomssen, C.
    Cortes-Funes, H.
    Biganzoli, L.
    Padrik, P.
    Zvirbule, Z.
    Smith, I.
    JOURNAL OF CLINICAL ONCOLOGY, 2009, 27 (15)
  • [24] Phase II Study of Bevacizumab in Combination with Docetaxel and Capecitabine for the First-Line Treatment of Patients with Locally Recurrent or Metastatic Breast Cancer
    Musolino, A.
    Bisagni, G.
    De Matteis, A.
    Nuzzo, F.
    Ardizzoni, A.
    Crino, L.
    Gamucci, T.
    Passalacqua, R.
    Gnoni, R.
    Boni, C.
    CANCER RESEARCH, 2010, 70
  • [25] A phase I study of dose-dense docetaxel (D) with cyclophosphamide (C) as first line in patients (pts) with metastatic breast cancer (MBC).
    Hocini, H
    Cottu, P
    Cuvier, C
    Romieux, G
    Culine, S
    Lerebours, F
    Espie, M
    Boccara, C
    Marty, M
    ANNALS OF ONCOLOGY, 2000, 11 : 24 - 24
  • [26] TANIA: A Randomized Phase III Trial Evaluating Continued and Reintroduced Bevacizumab (BEV) in Patients Previously Treated with 1st-Line BEV for Locally Recurrent/Metastatic Breast Cancer (LR/mBC).
    von Minckwitz, G.
    Cortes, J.
    Gligorov, J.
    Marschner, N. W.
    Puglisi, F.
    Vrdoljak, E.
    Duenne, A-A
    Zielinski, C.
    CANCER RESEARCH, 2011, 71
  • [27] Biomarkers as potential predictors of response to treatment with motesanib or bevacizumab in combination with paclitaxel (P) in patients (pts) with locally recurrent or advanced metastatic breast cancer (MBC)
    Patterson, S. D.
    Davis, M. T.
    Mackey, J. R.
    Martin, M.
    Hei, Y.
    Bass, M. B.
    JOURNAL OF CLINICAL ONCOLOGY, 2010, 28 (15)
  • [28] A randomized, placebo-controlled phase II study of AMG 386 plus bevacizumab (Bev) and paclitaxel (P) or AMG 386 plus P as first-line therapy in patients (pts) with HER2-negative, locally recurrent or metastatic breast cancer (LR/MBC)
    Dieras, V.
    Jassem, J.
    Dirix, L. Y.
    Guastalla, J. P.
    Bono, P.
    Hurvitz, S. A.
    Goncalves, A.
    Romieu, G.
    Limentani, S. A.
    Jerusalem, G. H. M.
    Lakshmaiah, K.
    Roche, H. H.
    Sanchez-Rovira, P.
    Pienkowski, T.
    Segui-Palmer, M. A.
    Li, A.
    Sun, Y.
    Pickett-Gies, C. A.
    Wildiers, H.
    JOURNAL OF CLINICAL ONCOLOGY, 2011, 29 (15)
  • [29] Vinorelbine metronomic plus bevacizumab as salvage therapy for patients with metastatic breast cancer (MBC): A multicenter phase II study
    Saloustros, E. S.
    Kalbakis, K.
    Vardakis, N. K.
    Kalykaki, A.
    Milaki, G.
    Rovithi, M.
    Agelaki, S.
    Saridaki, Z.
    Georgoulias, V.
    Mavroudis, D.
    JOURNAL OF CLINICAL ONCOLOGY, 2010, 28 (15)
  • [30] Final analysis of PUFFIN: A phase III, randomised double-blind, placebo (Pla)-controlled study of pertuzumab, trastuzumab and docetaxel (PHD) for Chinese patients (pts) with previously untreated HER2-positive locally recurrent or metastatic breast cancer (LR/MBC)
    Xu, B.
    Li, W.
    Zhang, Q.
    Li, Q.
    Wang, X.
    Li, H.
    Sun, T.
    Yin, Y.
    Zheng, H.
    Feng, J.
    Zhu, H.
    Siddiqui, A.
    Macharia, H. N.
    Knott, A.
    ANNALS OF ONCOLOGY, 2022, 33 : S217 - S218
12345